Gilead Sciences (GILD) Enterprise Value (2009 - 2026)
Gilead Sciences' (GILD) quarterly Enterprise Value came in at -$7.7 billion in Q1 2026, up 3.53% YoY from -$7.5 billion in Q1 2025, and little changed on a QoQ basis from -$7.7 billion in Q4 2025.
Gilead Sciences (GILD) Enterprise Value (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has 18 years of Enterprise Value data on file, last reported at -$7.7 billion in Q1 2026.
- Quarterly Enterprise Value rose 3.53% year-over-year to -$7.7 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$7.7 billion (up 3.53% YoY) and the FY2025 annual result came in at -$7.7 billion, up 23.41% from the prior year.
- Enterprise Value was little changed at -$7.7 billion in Q1 2026, from -$7.7 billion in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$2.9 billion in Q2 2024 to a low of -$10.1 billion in Q4 2024.
- A 5-year average of -$6.4 billion and a median of -$6.4 billion in 2022 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2024 — Enterprise Value surged 57.57% — and 2025, when it tumbled 85.47%.
- Tracing GILD's Enterprise Value over 5 years: stood at -$6.4 billion in 2022, then fell by 14.53% to -$7.3 billion in 2023, then slumped by 37.11% to -$10.1 billion in 2024, then grew by 23.41% to -$7.7 billion in 2025, then slipped by 0.14% to -$7.7 billion in 2026.
- The last three Enterprise Value figures came in at -$7.7 billion (Q1 2026), -$7.7 billion (Q4 2025), and -$7.4 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | -20.76 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | -6.52 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | -7.09 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | -7.69 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | -4.90 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | -13.99 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | -3.26 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | -11.40 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -4.80 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | -6.96 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.26 Bn |
| Mar 31, 2026 | -7.73 Bn |
| Dec 31, 2025 | -7.72 Bn |
| Sep 30, 2025 | -7.43 Bn |
| Jun 30, 2025 | -5.30 Bn |
| Mar 31, 2025 | -8.01 Bn |
| Dec 31, 2024 | -10.08 Bn |
| Sep 30, 2024 | -5.12 Bn |
| Jun 30, 2024 | -2.86 Bn |
| Mar 31, 2024 | -4.80 Bn |
| Dec 31, 2023 | -7.35 Bn |
| Sep 30, 2023 | -6.94 Bn |
| Jun 30, 2023 | -6.73 Bn |
| Mar 31, 2023 | -5.93 Bn |
| Dec 31, 2022 | -6.42 Bn |
| Sep 30, 2022 | -5.68 Bn |
| Jun 30, 2022 | -5.68 Bn |
| Mar 31, 2022 | -5.34 Bn |
| Dec 31, 2021 | -6.53 Bn |
| Sep 30, 2021 | -5.74 Bn |